CoChat
Sign Up
Cited by 35

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

MG132, a proteasome inhibitor, enhances LDL uptake in HepG2 cells in vitro by regulating LDLR and PCSK9 expression

Yan, Hong, Ma, Yan-ling, Gui, Yu-zhou, Wang, Shu-mei, Wang, Xin-bo, Gao, Fei, Wang, Yi-ping·2014·Acta Pharmacologica Sinica
DOI 10.1038/aps.2014.52
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/aps.2014.52

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 38

  1. Kong WJ, Liu J, Jiang JD . Human low-density lipoprotein receptor gene and its regulation. J Mol Med 2006; 84: 29–36. · DOI
  2. Micheal SB, Goldstein JL . A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232: 34–47. · DOI · Paper page
  3. Costet P, Krempf M, Cariou B . PCSK9 and LDL cholesterol: unravelling the target to design the bullet. Trends Biochem Sci 2008; 33: 426–34. · DOI
  4. Tarugi P, Averna M, Di Leo E, Cefalu AB, Noto D, Magnolo L, et al. Molecular diagnosis of hypobetalipoproteinemia: an ENID review. Atherosclerosis 2007; 195: e19–27. · DOI
  5. Stein EA, Swergold GD . Potential of proprotein convertase subtilisin/kexin type 9 based therapeutics. Curr Atherosclerosis Reports 2013; 15: 310. · DOI
  6. Dubuc G, Chamberland A, Wassef H, Davignon J, Seidah NG, Bernier L, et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2004; 24: 1454–9. · DOI · Paper page
  7. Giugliano RP, Desai NR, Kohli P, Rogers WJ, Somaratne R, Huang F, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet 2012; 380: 2007–17. · DOI
  8. Yu X, Kem DC . Proteasome inhibition during myocardial infarction. Cardiovasc Res 2010; 85: 312–20. · DOI
  9. Dreger H, Westphal K, Weller A, Baumann G, Stangl V, Meiners S, et al. Nrf2-dependent upregulation of antioxidative enzymes: a novel pathway for proteasome inhibitor-mediated cardioprotection. Cardiovasc Res 2009; 83: 354–61. · DOI
  10. Ogura M, Ayaori M, Terao Y, Hisada T, Iizuka M, Takiguchi S, et al. Proteasomal inhibition promotes ATP-binding cassette transporter A1 (ABCA1) and ABCG1 expression and cholesterol efflux from macrophages in vitro and in vivo. Arteriosclerosis Thromb Vasc Biol 2011; 31: 1980–7. · DOI
  11. Stephan ZF, Yurachek EC . Rapid fluorometric assay of LDL receptor activity by DiI-labeled LDL. J Lipid Res 1993; 34: 325–30. · DOI
  12. Li H, Dong B, Park SW, Lee HS, Chen W, Liu J . Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. J Biol Chem 2009; 284: 28885–95. · DOI
  13. Balasubramanian S, Kanade S, Han B, Eckert RL . A proteasome inhibitor-stimulated Nrf1 protein-dependent compensatory increase in proteasome subunit gene expression reduces polycomb group protein level. J Biol Chem 2012; 287: 36179–89. · DOI
  14. Hirano Y, Yoshida M, Shimizu M, Sato R . Direct demonstration of rapid degradation of nuclear sterol regulatory element-binding proteins by the ubiquitin-proteasome pathway. J Biol Chem 2001; 276: 36431–7. · DOI · Paper page
  15. Cao A, Wu M, Li H, Liu J . Janus kinase activation by cytokine oncostatin M decreases PCSK9 expression in liver cells. J Lipid Res 2011; 52: 518–30. · DOI
  16. Hussain MM, Strickland DK, Bakillah A . The mammalian low-density lipoprotein receptor family. Ann Rev Nutr 1999; 19: 141–72. · DOI
  17. Eberle D, Hegarty B, Bossard P, Ferre P, Foufelle F . SREBP transcription factors: master regulators of lipid homeostasis. Biochimie 2004; 86: 839–48. · DOI
  18. Inagaki K, Churchill E, Mochly-Rosen D . Epsilon protein kinase C as a potential therapeutic target for the ischemic heart. Cardiovasc Res 2006; 70: 222–30. · DOI
  19. Bright R, Sun GH, Yenari MA, Steinberg GK, Mochly-Rosen D . epsilonPKC confers acute tolerance to cerebral ischemic reperfusion injury. Neurosci Lett 2008; 441: 120–4. · DOI
  20. Wilson1 GM, Vasa MZ, Deeley RG . Stabilization and cytoskeletal-association of LDL receptor mRNA are mediated by distinct domains in its 3′ untranslated region. J Lipid Res 1998; 39: 1025–32. · DOI · Paper page
  21. Huang W, Mishra V, Batra S, Dillon I, Mehta KD . Phorbol ester promotes histone H3-Ser10 phosphorylation at the LDL receptor promoter in a protein kinase C-dependent manner. J Lipid Res 2004; 45: 1519–27. · DOI
  22. Mehta KD, Radominska-Pandya A, Kapoor GS, Dave B, Atkins BA . Critical role of diacylglycerol- and phospholipid-regulated protein kinase C in induction of low-density lipoprotein receptor transcription in response to depletion of cholesterol. Mol Cell Biol 2002; 22: 3783–93. · DOI
  23. Poulin B, Maccario H, Thirion S, Junoy B, Boyer B, Enjalbert A, et al. Ubiquitination as a priming process of PKC alpha and PKC epsilon degradation in the alphaT3-1 gonadotrope cell line. Neuroendocrinology 2009; 89: 252–66. · DOI
  24. Li Y, Lu W, Schwartz AL, Bu G . Degradation of the LDL receptor class 2 mutants is mediated by a proteasome-dependent pathway. J Lipid Res 2004; 45: 1084–91. · DOI
  25. Zelcer N, Hong C, Boyadjian R, Tontonoz P . LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science 2009; 325: 100–4. · DOI · Paper page
  26. Kourimate S, Le May C, Langhi C, Jarnoux AL, Ouguerram K, Zair Y, et al. Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9. J Biol Chem 2008; 283: 9666–73. · DOI
  27. Langhi C, Le May C, Kourimate S, Caron S, Staels B, Krempf M, et al. Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes. FEBS Lett 2008; 582: 949–55. · DOI
  28. Costet P, Cariou B, Lambert G, Lalanne F, Lardeux B, Jarnoux AL, et al. Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c. J Biol Chem 2006; 281: 6211–8. · DOI
  29. Kohjima M, Higuchi N, Kato M, Kotoh K, Yoshimoto T, Fujino T, et al. SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease. Int J Mol Med 2008; 21: 5.
  30. Zhou R, Wang L, Xu X, Chen J, Hu LH, Chen LL, et al. Danthron activates AMP-activated protein kinase and regulates lipid and glucose metabolism in vitro. Acta Pharmacol Sin 2013; 34: 1061–9. · DOI
  31. Repa JJ . Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Develop 2000; 14: 2819–30. · DOI
  32. Kohjima M, Higuchi N, Kato M, Kotoh K, Yoshimoto T, Fujino T, et al. SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease. Int J Mol Med 2008; 21: 507–11.
  33. Li C . Induction of low density lipoprotein receptor (LDLR) transcription by oncostatin M is mediated by the extracellular signal-regulated kinase signaling pathway and the repeat 3 element of the LDLR promoter. J Biol Chem 1999; 274: 6747–53. · DOI
  34. Adams J . Proteasome inhibitors as therapeutic agents. Expert Opin Ther Patents 2003; 13: 45–57. · DOI
  35. Meiners S . Ubiquitin-proteasome pathway as a new target for the prevention of restenosis. Circulation 2002; 105: 483–9. · DOI
  36. Meiners S, Dreger H, Fechner M, Bieler S, Rother W, Gunther C, et al. Suppression of cardiomyocyte hypertrophy by inhibition of the ubiquitin-proteasome system. Hypertension 2008; 51: 302–8. · DOI
  37. Wilck N, Fechner M, Dreger H, Hewing B, Arias A, Meiners S, et al. Attenuation of early atherogenesis in low-density lipoprotein receptor-deficient mice by proteasome inhibition. Arteriosclerosis Thromb Vasc Biol 2012; 32: 1418–26. · DOI
  38. Herrmann J, Saguner AM, Versari D, Peterson TE, Chade A, Olson M, et al. Chronic proteasome inhibition contributes to coronary atherosclerosis. Circ Res 2007; 101: 865–74. · DOI

Cited by

Sorted by citations

Metadata

Authors
Yan, H., Ma, Y.-L., Gui, Y.-Z., Wang, S.-M., Wang, X.-B., Gao, F., & Wang, Y.-P.
Venue
Acta Pharmacologica Sinica
Publisher
Springer Science and Business Media LLC
Published
2014-07-21
Volume
35
Issue
8
Pages
994-1004
ISSN
  • 1671-4083
  • 1745-7254
DOI
10.1038/aps.2014.52
Cited by
35
References
1
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review